CU20120147A7 - Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato - Google Patents

Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato

Info

Publication number
CU20120147A7
CU20120147A7 CUP2012000147A CU20120147A CU20120147A7 CU 20120147 A7 CU20120147 A7 CU 20120147A7 CU P2012000147 A CUP2012000147 A CU P2012000147A CU 20120147 A CU20120147 A CU 20120147A CU 20120147 A7 CU20120147 A7 CU 20120147A7
Authority
CU
Cuba
Prior art keywords
amino
methylpyridine
carboxamide
phenyl
preparation
Prior art date
Application number
CUP2012000147A
Other languages
English (en)
Other versions
CU24123B1 (es
Inventor
Juergen Stiehl
Werner Heilmann
Michael Lögers
Joachim Rehse
Michael Gottfried
Saskia Wichmann
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120147(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20120147A7 publication Critical patent/CU20120147A7/es
Publication of CU24123B1 publication Critical patent/CU24123B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida,sus sales y su monohidrato.
CU20120147A 2010-04-15 2011-04-08 Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato CU24123B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15
PCT/EP2011/055508 WO2011128261A1 (en) 2010-04-15 2011-04-08 Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate

Publications (2)

Publication Number Publication Date
CU20120147A7 true CU20120147A7 (es) 2013-01-30
CU24123B1 CU24123B1 (es) 2015-08-27

Family

ID=44070712

Family Applications (2)

Application Number Title Priority Date Filing Date
CU20120147A CU24123B1 (es) 2010-04-15 2011-04-08 Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato
CU2014000060A CU20140060A7 (es) 2010-04-15 2014-05-26 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato

Family Applications After (1)

Application Number Title Priority Date Filing Date
CU2014000060A CU20140060A7 (es) 2010-04-15 2014-05-26 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato

Country Status (40)

Country Link
US (5) US8748622B2 (es)
EP (1) EP2558448B1 (es)
JP (1) JP5934182B2 (es)
KR (2) KR101800041B1 (es)
CN (2) CN103980191A (es)
AR (2) AR081060A1 (es)
AU (1) AU2011240113B2 (es)
BR (1) BR112012026117B1 (es)
CA (1) CA2796238C (es)
CL (1) CL2012002840A1 (es)
CO (1) CO6630136A2 (es)
CR (1) CR20120526A (es)
CU (2) CU24123B1 (es)
DK (1) DK2558448T3 (es)
DO (2) DOP2012000268A (es)
EC (1) ECSP12012234A (es)
ES (1) ES2542610T3 (es)
GT (1) GT201200280A (es)
HK (1) HK1200831A1 (es)
HR (1) HRP20150885T1 (es)
HU (1) HUE026821T2 (es)
IL (2) IL222348B (es)
JO (1) JO3158B1 (es)
MA (1) MA34156B1 (es)
MX (1) MX2012011734A (es)
MY (2) MY177066A (es)
NZ (1) NZ602997A (es)
PE (2) PE20160838A1 (es)
PH (1) PH12012502060A1 (es)
PL (1) PL2558448T3 (es)
PT (1) PT2558448E (es)
RS (1) RS54219B1 (es)
RU (1) RU2581585C2 (es)
SG (2) SG10201501221UA (es)
SI (1) SI2558448T1 (es)
TN (1) TN2012000492A1 (es)
TW (2) TWI539951B (es)
UA (1) UA110613C2 (es)
UY (2) UY33290A (es)
WO (1) WO2011128261A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005289100B2 (en) * 2004-09-29 2011-11-03 Bayer Healthcare Llc Thermodynamically stable form of bay 43-9006 tosylate
DE602006017188D1 (de) 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
HRP20181462T1 (hr) 2012-09-25 2018-11-02 Bayer Pharma Aktiengesellschaft Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
WO2015049698A2 (en) * 2013-10-04 2015-04-09 Hetero Research Foundation Process for regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
US9790185B2 (en) 2014-07-09 2017-10-17 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
SG11201806116SA (en) * 2016-01-18 2018-08-30 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
PT3630112T (pt) 2017-06-02 2024-04-23 Bayer Healthcare Llc Combinação de regorafenib e nivolumab para tratamento de cancro
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP2305255B1 (en) 2001-12-03 2012-08-22 Bayer HealthCare LLC Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
CA2578442A1 (en) 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation Pharmaceutical compositions comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide for the treatment of cancer
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
AU2005289100B2 (en) 2004-09-29 2011-11-03 Bayer Healthcare Llc Thermodynamically stable form of bay 43-9006 tosylate
ES2532377T3 (es) 2004-09-29 2015-03-26 Bayer Healthcare Llc Procedimiento de preparación de 4-{4-[({[4-[cloro-3-(trifluorometil)fenil]amino}carbonil) amino]fenoxi}N-metilpiridina-2-carboxamida
DE602006017188D1 (de) 2005-03-07 2010-11-11 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
EP1954272A2 (en) 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
JP2009515978A (ja) 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008055629A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
CA2673041A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
US20100173954A1 (en) 2007-01-19 2010-07-08 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
ES2429107T3 (es) 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CA2741087A1 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
CA2760179A1 (en) 2009-05-15 2010-11-18 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
JP2013538840A (ja) 2010-10-01 2013-10-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−（２−アリールアミノ）アリールスルホンアミドを含有する組み合わせ
CA2840491A1 (en) 2011-06-28 2013-01-03 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sorafenib
EA201400064A1 (ru) 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
JO3479B1 (ar) 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب

Also Published As

Publication number Publication date
RU2581585C2 (ru) 2016-04-20
IL222348A0 (en) 2012-12-31
CO6630136A2 (es) 2013-03-01
CU20140060A7 (es) 2014-10-02
KR20130061670A (ko) 2013-06-11
TW201204356A (en) 2012-02-01
KR101800041B1 (ko) 2017-11-21
IL222348B (en) 2018-08-30
EP2558448B1 (en) 2015-05-20
AU2011240113B2 (en) 2014-12-18
EP2558448A1 (en) 2013-02-20
CA2796238A1 (en) 2011-10-20
UY39590A (es) 2022-01-31
PL2558448T3 (pl) 2015-10-30
CN102947271B (zh) 2016-11-09
TN2012000492A1 (en) 2014-04-01
US9458107B2 (en) 2016-10-04
US8748622B2 (en) 2014-06-10
JP5934182B2 (ja) 2016-06-15
RS54219B1 (sr) 2015-12-31
HK1200831A1 (en) 2015-08-14
SI2558448T1 (sl) 2015-11-30
CL2012002840A1 (es) 2013-01-18
PT2558448E (pt) 2015-09-01
JO3158B1 (ar) 2017-09-20
PE20160838A1 (es) 2016-09-24
ES2542610T3 (es) 2015-08-07
TWI475992B (zh) 2015-03-11
MY177066A (en) 2020-09-03
HUE026821T2 (en) 2016-07-28
IL253119A0 (en) 2017-08-31
BR112012026117B1 (pt) 2022-08-30
US10822305B2 (en) 2020-11-03
HRP20150885T1 (hr) 2015-10-09
TW201509415A (zh) 2015-03-16
CU24123B1 (es) 2015-08-27
MX2012011734A (es) 2012-12-17
UY33290A (es) 2011-12-01
SG10201501221UA (en) 2015-04-29
AR116395A2 (es) 2021-05-05
MY162359A (en) 2017-06-15
DOP2016000285A (es) 2016-11-30
BR112012026117A2 (pt) 2015-09-08
US20170334857A1 (en) 2017-11-23
WO2011128261A1 (en) 2011-10-20
US20130116442A1 (en) 2013-05-09
KR20170129276A (ko) 2017-11-24
CA2796238C (en) 2019-12-31
US20170057918A1 (en) 2017-03-02
DK2558448T3 (en) 2015-08-24
CN103980191A (zh) 2014-08-13
GT201200280A (es) 2014-07-23
SG184172A1 (en) 2012-11-29
BR112012026117A8 (pt) 2017-12-19
NZ602997A (en) 2014-10-31
US20140221661A1 (en) 2014-08-07
TWI539951B (zh) 2016-07-01
ECSP12012234A (es) 2012-11-30
MA34156B1 (fr) 2013-04-03
PH12012502060A1 (en) 2013-02-04
AU2011240113A1 (en) 2012-10-11
JP2013523851A (ja) 2013-06-17
CN102947271A (zh) 2013-02-27
RU2012148386A (ru) 2014-05-20
CR20120526A (es) 2013-03-11
IL253119B (en) 2018-03-29
US20190144391A1 (en) 2019-05-16
PE20130181A1 (es) 2013-02-23
AR081060A1 (es) 2012-06-06
DOP2012000268A (es) 2012-12-15
UA110613C2 (uk) 2016-01-25

Similar Documents

Publication Publication Date Title
DOP2016000285A (es) Procedimiento para la preparación de 4-­{4-­[({[4-­cloro-­3-­(trifluorometil)fenil]amino}carbonil)amino]-­3-­fluorofenoxi}-­n-­metilpiridina-­2-­carboxamida, sus sales y su monohidrato
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
BR112013020611A2 (pt) método para produção de compostos quelato de aminoácido, compostos quelato de aminoácido e uso de compostos quelato de aminoácido
DK2760444T3 (da) Cannabinoidcarboxylsyrer, salte af cannabinoidcarboxylsyrer, fremstilling og anvendelse deraf
CY1117163T1 (el) Ιμιδαζοπυριδαζινες ως αναστολεις κινασης ακτ
BR112013021775A2 (pt) bactéria corineforme, e, método para produzir um l-aminoácido
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
BR112012020629A2 (pt) forma cristalina, e, método para a terapia de um distúrbio
HK1205095A1 (en) Methods and intermediates for preparing pharmaceutical agents
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
BR112014006735A2 (pt) tabaco tendo reduzidas quantidades de aminoácidos e métodos para a produção de tais linhas
EA201100230A1 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
UA111329C2 (uk) Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою
UA118008C2 (uk) Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
UA117900C2 (uk) Спосіб синтезу 3-(2-бром-4,5-диметоксифеніл)пропаннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
UA111156C2 (uk) Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою
EA201300281A2 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
EA201301020A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
UY34626A (es) Proceso para la preparación estereoselectiva de pirazol carboxamida y compuestos intermediarios

Legal Events

Date Code Title Description
FG Grant of patent